Clinical Trial Update: Humoral Immunodeficiency in CLL and Therapy With Subcutaneous Ig [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 trial update evaluating humoral immunodeficiency in chronic lymphocytic leukemia (CLL) and therapy with subcutaneous immunoglobulin.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Humoral Immunodeficiency

Drugs mentioned

• Ig replacement therapy (immunoglobulin)
• Subcutaneous immunoglobulin (immunoglobulin)

Snippet

Sponsor: Rochester General Hospital | Conditions: Secondary Immune Deficiency Disorder | Phase 2, Phase 3 | Status: COMPLETED